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amilla Smith, MD,* Jan K. Damås, MD, PHD,* Kari Otterdal, MSC,* Erik Øie, MD, PHD,†‡
iggo J. Sandberg, MSC,* Arne Yndestad, PHD,* Torgun Wæhre, MD, PHD,* Hanne Scholz, PHD,*
nut Endresen, MD, PHD,‡ Peder S. Olofsson, MD, Bente Halvorsen, PHD,* Lars Gullestad, MD, PHD,‡
tig S. Frøland, MD, PHD,*§ Gøran K. Hansson, MD, PHD, Pål Aukrust, MD, PHD*§
slo, Norway; and Stockholm, Sweden
OBJECTIVES We sought to investigate the role of the CXC chemokine neutrophil-activating peptide-2
(NAP-2) in atherogenesis and plaque destabilization.
BACKGROUND Chemokines are involved in atherogenesis, but the role of NAP-2 in atherosclerotic disorders
is unclear. Based on its potential pro-atherogenic properties, we hypothesized a pathogenic
role for NAP-2 in coronary artery disease.
METHODS We tested this hypothesis by differential experimental approaches including studies in
patients with stable (n 40) and unstable angina (n 40) and healthy control subjects (n 20).
RESULTS The following results were discovered: 1) patients with stable, and particularly those with
unstable, angina had markedly raised plasma levels of NAP-2 compared with control subjects,
accompanied by increased expression of CXC receptor 2 in monocytes; 2) platelets, but also
peripheral blood mononuclear cells (PBMCs), released large amounts of NAP-2 upon
stimulation, with a particularly prominent PBMC response in unstable angina; 3) NAP-2
protein was detected in macrophages and smooth muscle cells of atherosclerotic plaques and
in monocytes and platelets of coronary thrombi; 4) in vitro, recombinant and platelet-derived
NAP-2 increased the expression of adhesion molecules and chemokines in endothelial cells;
and 5) whereas aspirin reduced plasma levels of NAP-2, statin therapy increased NAP-2 with
stimulating effects both on platelets and leukocytes.
CONCLUSIONS Our findings suggest that NAP-2 has the potential to induce inflammatory responses within
the atherosclerotic plaque. By its ability to promote leukocyte and endothelial cell activation,
such a NAP-2-driven inflammation could promote plaque rupture and acute coronary
syndromes. (J Am Coll Cardiol 2006;48:1591–9) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.06.060Cardiology Foundation
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Phemokines are involved in atherogenesis and plaque de-
tabilization by activating and directing leukocytes into
therosclerotic lesion (1). Enhanced expression of monocyte
hemoattractant protein (MCP)-1 is found within athero-
clerotic plaques in humans, and targeted disruption of the
enes for MCP-1 and its receptor significantly decrease
therosclerotic lesion formation in mice prone to develop
therosclerosis (1). Although much focus has been directed
gainst the role of CXC chemokines in inflammatory lung
isease, recent studies in gene-modified mice suggest that
hese chemokines (e.g., interleukin [IL]-8/CXC receptor 2
CXCR2]) may also be involved in atherogenesis (2).
lthough the role of chemokines in atherosclerosis has been
xtensively studied in various animal models, their involve-
ent in human coronary artery disease (CAD) has not been
ully clarified.
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nfectious Diseases, Rikshospitalet University Hospital, University of Oslo, Oslo,
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arolinska University Hospital, Stockholm, Sweden. This work was supported by
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oundation, Research Council of Norway, the University of Oslo, and Medinnova
oundation. Drs. Dama˙s and Otterdal contributed equally to this work.t
Manuscript received April 21, 2006; revised manuscript received June 6, 2006,
ccepted June 19, 2006.Chemokines can be produced by a variety of cells includ-
ng leukocytes, endothelial cells, and platelets. Upon acti-
ation, platelets release significant amounts of various che-
okines such as regulated on activation normally T-cell
xpressed and secreted (RANTES), promoting inflamma-
ion in adjacent leukocytes and endothelial cells (3). Acti-
ated platelets also release large quantities of neutrophil-
ctivating peptide-2 (NAP-2) through proteolytic
onversion from its precursors beta-thromboglobulin and
onnective tissue-activating protein III (4). Through inter-
ction with its receptors CXCR1 and CXCR2, NAP-2
nduces chemotaxis of neutrophils and monocytes and
eutrophil degranulation (4). Although several studies sup-
ort a pathogenic role for its receptors in atherogenesis (1),
ew studies have examined the role of NAP-2 in human
AD.
Based on its potential pro-atherogenic properties, we
ypothesized a pathogenic role for NAP-2 in atherogenesis
nd plaque destabilization. Herein we investigated this
ypothesis by differential experimental approaches.
ETHODS
atients and control subjects. Patients with angina pec-
oris were consecutively recruited into the study (Table 1).
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NAP-2 in Coronary Artery Disease October 17, 2006:1591–9ll patients with unstable angina (n  40) had experienced
schemic chest pain at rest within the preceding 48 h (i.e.,
raunwald’s class IIIB), but with no evidence of myocardial
ecrosis by enzymatic criteria. Transient ST-T segment
epression and/or T-wave inversion was present in all cases.
ll patients with stable angina (n  40) had stable effort
ngina of 6 months duration and a positive exercise test.
he diagnosis of CAD was confirmed in all patients by
oronary angiography showing at least 1-vessel disease
50% narrowing of luminal diameter). Exclusion criteria
ere myocardial infarction (MI) or thrombolytic therapy in
he previous month, concomitant inflammatory diseases
uch as infections and autoimmune disorders, and liver or
idney disease. In patients undergoing percutaneous coro-
ary intervention (PCI), all blood samples were taken before
his procedure. Blood samples were taken 12 h after the
Abbreviations and Acronyms
CAD  coronary artery disease
ELISA  enzyme-linked immunosorbent assay
HUVEC  human umbilical vein endothelial cell
IL  interleukin
LPS  lipopolysaccharide
MCP  monocyte chemoattractant protein
MI  myocardial infarction
NAP  neutrophil-activating peptide
oxLDL  oxidized low-density lipoprotein
PBMC  peripheral blood mononuclear cell
PCI  percutaneous coronary intervention
PHA  phytohemagglutinin
PRP  platelet-rich plasma
rh  recombinant human
SMC  smooth muscle cell
STEMI  ST-segment elevation myocardial infarction
VCAM  vascular cellular adhesion molecule
Table 1. Characteristics of the Study Group
Controls
(n  20)
Age, yrs  SD 59  6
Gender, females/males 3/17
Smokers, % 10
Hypertension,* % 0
Diabetes,* % 0
Medication,* %
Beta-blockers 0
Aspirin 0
Statins 0
Calcium antagonists 0
LMWH 0
Warfarin 0
Clopidogrel 0
Gp IIb/IIIa antagonists 0
Total cholesterol, mmol/l 4.3  0.6
LDL cholesterol, mmol/l 2.6  0.6
HDL cholesterol, mmol/l 1.4  0.3
Triglycerides, mmol/l 1.5  0.4
Data are mean  SEM. *p values indicate the difference be
Gp  glycoprotein; HDL  high-density lipoprotein; LDL 
heparin; Statins  hydroxymethylglutaryl coenzyme A reductase inast dosage of low molecular weight heparin. Control
ubjects in the study were 20 healthy blood donors (Table 1).
nformed consent for participation in the study was obtained
rom all individuals. All parts of the study were approved by the
ocal ethical committee. Blood samples (platelet-poor plasma)
ere collected as previously described (5).
solation of cells. Peripheral blood mononuclear cells
PBMCs) were obtained from heparinized blood by Isopaque-
icoll (Lymphoprep; Nycomed, Oslo, Norway) gradient cen-
rifugation. Further separation of CD14 monocytes and
D3 T-cells was performed as described elsewhere (6).
ell culture experiments. Peripheral blood mononuclear
ells were incubated in 96-well trays (2  106/ml; Costar,
ambridge, Massachusetts), in medium alone (RPMI 1640
ith 2 mmol/l L-glutamine and 25 mmol/l HEPES buffer
Gibco, Paisley, United Kingdom]) supplemented with
0% fetal calf serum (Sigma, St. Louis, Missouri) or
timulated with phytohemagglutinin (PHA) (Murex, Drat-
ord, United Kingdom; final dilution 1:100) or lipopolysac-
haride (LPS) from Escherichia coli O26:B6 (Sigma; 10
g/ml). In some experiments, cells were incubated with the
torvastatin metabolite ortho-hydroxy atorvastatin (gift
rom Pfizer, New York, New York). The human monocytic
ell line THP-1 (American Type Culture Collection, Rock-
ille, Maryland) was differentiated into macrophages and
ultured as described (7), with or without oxidized low-
ensity lipoprotein (oxLDL, 20 g/ml). Human aortic
mooth muscle cells (SMCs) were obtained from Promo-
ell (Heidelberg, Germany) and grown in SMC Growth
edium 2 with complete supplement mix (PromoCell). At
xperimental start, the cells were cultured with and without
xLDL (20 g/ml) in 24-well plates (1.5  105 cells/ml;
ostar). Primary human umbilical vein endothelial cells
HUVECs) were obtained from umbilical cord veins and
Angina
 40)
Unstable Angina
(n  40) p Value
 8 61  11 0.340
/35 13/27 0.032
20 16 0.346
10 28 0.094
5 10 0.396
83 100 0.006
75 92 0.034
80 86 0.556
22 11 0.239
0 100 0.001
8 3 0.305
23 78 0.001
0 8 0.076
 0.7 4.9  0.8 0.656
 0.6 3.4  0.6 0.833
 0.5 1.2  0.6 0.798
 0.5 1.7  0.6 0.654
stable and unstable angina.Stable
(n
66
5
4.8
3.3
1.2
1.6
tween
low-density lipoprotein; LMWH  low molecular weight
hibitors.
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October 17, 2006:1591–9 NAP-2 in Coronary Artery Diseaseultured as described (5). Human umbilical vein endothelial
ells were stimulated with oxLDL (20 g/ml) or different
oncentrations of recombinant human NAP-2 (rhNAP-2;
&D Systems, Minneapolis, Minnesota) and rhIL-8
R&D Systems) with and without anti-human CXCR1 and
nti-human CXCR2 antibodies or isotype-matched control
ouse IgG2A (50 g/ml for all antibodies; R&D Systems).
t different time points, cell-free supernatants and cell
ellets from PBMCs, THP-1 cells, vascular SMCs, and
UVECs were harvested and stored at 80°C. In the
UVEC cultures, the confluent cell layer was prepared for
ellular enzyme-linked immunosorbent assay (ELISA).
ow-density lipoprotein was isolated from human
ndotoxin-free heparin plasma and oxidatively modified by
u2 ions (7). The endotoxin levels of all stimulants and
ulture media were 10 pg/ml (Limulus Amebocyte Assay,
elson Laboratories, Salt Lake City, Utah).
hemotaxis assay. Chemotactic activities were estimated
n 24-well Transwell plates (Costar) using polycarbonate
embranes with 8 m pore size (Falcon; Becton Dickinson
abware, Bedford, Massachusetts). The lower chamber
ontained 800 l RPMI 1640 with 0.5% bovine serum
lbumin, 20 mmol/l N-[2-hydroxyethyl]piperazine-N=-[2-
thanesulfonic acid] (HEPES), pH 7.4 (buffer A), and
hNAP-2 (R&D Systems). To estimate random migration,
he chemokine was omitted in negative control experiments.
reshly isolated monocytes (2.5  105/200 l buffer A)
ere loaded into the upper chamber, incubated at 37°C for
0 min, and the cells attached to the side of the polycar-
onate membrane in contact with the cell suspension were
emoved. After fixation with 1% glutaraldehyde, the mi-
rated cells adhering to the membranes were stained with
rystal violet and counted under an inverted microscope.
timulation of platelet-rich plasma (PRP). Citrated PRP
as incubated at room temperature after addition of 100
l/l of the thrombin receptor agonist peptide SFLLRN
The Biotechnology Centre of Oslo, Oslo, Norway) or
ris-buffered saline only (8). At baseline and after 30 min,
RP was centrifuged at 10,000 g for 10 min, and platelet-
ree plasma and platelet pellets (with Tris-buffered saline)
ere stored separately at80°C. In some experiments, PRP
as pre-incubated with ortho-hydroxy atorvastatin for 30
in before addition of SFLLRN. Platelet pellets were lysed
5), and the NAP-2 levels were analyzed in the lysates. The
ncrease in chemokine levels (ng/108 platelets) was ex-
ressed as the concentration in platelet-free plasma at the
nd of the experiments minus the concentration at baseline.
ncubation of HUVECs with platelet extracts. Prepara-
ion of extract from resting platelets was performed as
reviously described (5). The platelet extract, prepared from
solution of 109 platelets/ml, was added to confluent
UVECs in 96-well trays for stimulation for 5 h. To block
or platelet-derived NAP-2-mediated effects, a NAP-2
eutralizing and an irrelevant isotype-matched antibody (20
g/ml; R&D Systems) were added to the platelet extract
efore exposing it to HUVECs. The anti–NAP-2 antibody bose-dependently inhibits rhNAP-2 bioactivity with no
ross-reactivity with other platelet-derived cytokines, but we
annot totally exclude that this antibody could interfere with
he NAP-2 precursors.
eal-time quantitative reverse transcription-polymerase
hain reaction. Total RNA was extracted from PBMCs,
onocytes, and T-cells using RNeasy columns (Qiagen,
ilden, Germany), subjected to DNase I treatment (RQI
Nase; Promega, Madison, Wisconsin), and stored in
NA storage solution (Ambion, Austin, Texas) at 80°C.
rimers were designed using the Primer Express software,
ersion 2.0 (Applied Biosystems, Foster City, California).
rimer sequences could be provided by request. Quantifi-
ation of mRNA was performed using the ABI Prism 7000
Applied Biosystems) (6). Gene expression of the house-
eeping gene beta-actin (Applied Biosystems) was used for
ormalization.
issue sampling of thrombus materials. In 8 patients
ith acute ST-segment elevation myocardial infarction
STEMI) undergoing PCI, thrombi at the site of the
cclusion were aspirated immediately after crossing the
esion with the guidewire (5). The aspirated solid material
as fixed in 4% paraformaldehyde and embedded in
araffin.
issue sampling from carotid plaque. Atherosclerotic
laques representing type VI lesions were obtained from
atients undergoing carotid endarterectomy due to transient
schemic attacks (9). As controls, non-atherosclerotic hu-
an renal artery samples were taken from patients under-
oing nephrectomy due to non-metastatic renal carcinoma.
mmunohistochemistry. Paraformaldehyde-fixed sections
f thrombus material and acetone-fixed sections of carotid
laques and renal arteries were stained using monoclonal
ouse anti-human NAP-2, mouse anti-human CXCR1,
ouse anti-human CXCR2 (all from R&D Systems), mouse
nti-human CD41 (Immunotech, Marseille, France) anti-
odies, and affinity purified polyclonal mouse anti-human
onocyte/macrophage (calprotectin) IgG (MCA874G, Se-
otec, Oxford, United Kingdom). The primary antibodies
ere followed by biotinylated anti-mouse IgG (Vector
aboratories, Burlingame, California). The immunoreactiv-
ties were further amplified using avidin-biotin-peroxidase
omplexes (Vector Laboratories). Diaminobenzidine was
sed as the chromogen in a metal-enhanced system (Pierce
hemical, Rockford, Illinois). The sections were counter-
tained with hematoxylin. Omission of the primary anti-
ody served as negative control.
LISAs. Total cellular expression of E-selectin and vascu-
ar cellular adhesion molecule (VCAM)-1 was measured by
LISA on fixed adherent HUVECs (5). Levels of NAP-2,
CP-1, IL-8, and RANTES were measured by ELISAs
R&D Systems).
tatistical analysis. For comparison of 2 groups, the Mann-
hitney U test (2-tailed) was used. When more than 2
roups were compared, 1-way analysis of variance followed
y Scheffe’s post hoc test for statistical significance was used.
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NAP-2 in Coronary Artery Disease October 17, 2006:1591–9or comparisons within the same individuals, the Wilcoxon
igned rank test was used. Probability values (2-sided) were
onsidered significant at value of 0.05.
ESULTS
AP-2 levels in platelet-poor plasma. Both patients with
table (n  40) and particularly those with unstable (n 
0) angina had significantly increased plasma levels of
AP-2 comparing healthy control subjects (n  20) (Fig.
A). Although the CAD patients used medications with
otential platelet inhibitory effects (e.g., aspirin and warfa-
in), they still had raised NAP-2 levels. Despite the use of
ore aggressive platelet inhibition (i.e., clopidogrel and
lycoprotein IIb/IIIa antagonists) in the unstable angina
atients, they still had markedly raised NAP-2 levels.
lthough heparin may enhance platelet aggregation in-
uced by some platelet agonists (e.g., epinephrine), it
mpairs platelet activation in response to thrombin and
igure 1. (A) Shows plasma levels of neutrophil-activating peptide
NAP)-2 in 40 patients with unstable angina pectoris (AP), 40 patients
ith stable AP, and 20 healthy control subjects. (B and C) show mRNA
evels for the NAP-2 receptors CXCR2 (B) and CXCR1 (C) relative to
eta-actin mRNA in monocytes from 12 patients with unstable AP, 12
atients with stable AP, and 10 healthy control subjects. Data are mean
alues SEM. *p 0.05 and ***p 0.001 versus healthy control subjects;
p  0.05 versus stable AP. One-way analysis of variance followed byT
cheffe’s post hoc test for statistical significance was used for statistical
omparisons.ollagen (10), and it is very unlikely that the difference in
AP-2 levels between stable and unstable angina do not
erely reflect differences in the use of heparin (Table 1).
ome of the patients had additional risk factors that could
nterfere with platelet activation (e.g., diabetes and hyper-
ension), but the same pattern of NAP-2 levels was observed
ven if these patients were excluded from the study. There
as a higher proportion of women in the unstable compared
ith the stable angina group (Table 1), but we found the
ame pattern of NAP-2 levels in both genders.
he expression of NAP-2 receptors in monocytes and
-cells. When examining monocytes from 12 patients
ith unstable angina, 12 patients with stable angina, and 10
ealthy control subjects, we found that the increase in
AP-2 in unstable angina was accompanied by enhanced
ene expression of its corresponding receptors CXCR1 and
XCR2 in monocytes from these patients (Figs. 1B and
C). In contrast, these receptors were down-regulated in
-cells from unstable angina patients, but not in T-cells
rom stable angina patients, comparing healthy control
ubjects (data not shown) possibly reflecting down-
egulation of the receptors due to persistent exposure to
heir ligands or redistribution of CXCR1/2-positive T-cells
o the plaque in unstable angina.
he cellular source of NAP-2 in unstable angina. THE
ELEASE OF NAP-2 FROM PLATELETS. As expected, platelets
eleased large amounts of NAP-2 into the supernatants
pon SFLLRN stimulation in both stable angina patients
n  12), unstable angina patients (n  12), and healthy
ontrol subjects (n 10) (Fig. 2A). Although there were no
ifferences in the SFLLRN-stimulated release of NAP-2
etween patients and control subjects, platelet pellets from
nstable angina patients, but not from those with stable
ngina, contained significantly higher levels of NAP-2 than
latelet pellets from healthy control subjects (2.2  0.4 vs.
.9  0.1 g/108 platelets, p  0.05).
HE RELEASE OF NAP-2 FROM PBMCs. Neutrophil-
ctivating peptide-2 is considered to be a predominantly
latelet-derived chemokine, but also PBMCs released in-
reased amounts of this chemokine upon PHA and LPS
timulation (Fig. 2B). Although the increase in PBMCs
rom healthy control subjects (n  10) and stable angina
atients (n  12) was rather modest and non-significant,
espectively, cells from those with unstable angina (n  12)
eleased large amount of NAP-2, showing a significant
igher LPS- and PHA-mediated NAP-2 response than in
ealthy control subjects (Fig. 2B). An increase in NAP-2
as also seen at the mRNA level, suggesting that PBMCs
ave the ability to produce NAP-2 (data not shown).
HE RELEASE OF NAP-2 FROM VASCULAR SMCs AND THP-1
ACROPHAGES. We next examined the ability of oxLDL
o induce NAP-2 release in other cell types known to be
nvolved in atherogenesis, and oxLDL significantly induced
AP-2 release comparing unstimulated cells in both
HP-1 macrophages (0.094  0.028 vs. 0.169  0.035
n
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October 17, 2006:1591–9 NAP-2 in Coronary Artery Diseaseg/ml, p  0.05) and vascular SMCs (0.028  0.010 vs.
.106  0.026 ng/ml, p  0.05), but not in HUVECs.
owever, the amount of NAP-2 was rather modest com-
ared with the release in platelets and PBMCs (Fig. 2).
xpression of NAP-2 and its receptors in human athero-
clerotic lesions. When examining the expression of
AP-2 and its receptors in atherosclerotic plaques from 4
atients undergoing carotid endarterectomy surgery because
f symptomatic carotid stenosis, positive platelet staining
as observed, mainly near the luminal surface of the plaque,
ccompanied by NAP-2 immunoreactivity. However,
trong NAP-2 immunostaining was also seen in other parts
f the plaque, in areas with predominantly calprotectin-
ositive macrophages, and in vascular SMCs (data not
hown), without accompanying platelet staining (Fig. 3).
eutrophil-activating peptide-2 immunoreactivity was ac-
ompanied by immunostaining of its corresponding recep-
ors in the same regions. Immunostaining of NAP-2 and its
eceptors was not seen in non-atherosclerotic renal arteries
n  4) (Fig. 3).
xpression of NAP-2 in arterial thrombosis. We next
xamined the expression of NAP-2 in thrombus material
btained from 8 patients with STEMI undergoing primary
CI. Immunostaining of the material removed from the site
f plaque rupture showed large amounts of NAP-2 in
latelets and calprotectin-positive monocytes (Fig. 4). Also,
XCR1 and CXCR2 showed strong immunostaining in
hese samples, not only in calprotectin-positive monocytes,
ut also in areas with aggregated platelets (Fig. 4).
ffects of rhNAP-2 on monocyte chemotaxis. To map
ny pathogenic consequences of the enhanced NAP-2
evels in unstable angina, we examined the ability of
AP-2 to promote chemotaxis of monocytes from un-
table angina patients (n  5) and healthy control
ubjects (n  5). Recombinant NAP-2 significantly
nhanced monocyte chemotaxis in a dose-dependent
anner (1 to 100 ng/ml) in both unstable angina patients
nd control subjects with a more marked response in
nstable angina (40  6 vs. 65  8, migrated cells/field
igure 2. (A) Shows neutrophil-activating peptide (NAP)-2 levels in plate
latelets (incubated for 30 min) in 12 patients with unstable angina pector
ontrol subjects (white bars). (B) Shows the NAP-2 levels in Unstim and
ilution 1:100) stimulated peripheral blood mononuclear cells supernatants
ith stable AP (striped bars), and 10 healthy control subjects (white bars
p  0.05 versus healthy control subjects. One-way analysis of variance fol
omparisons.t 100 ng/ml NAP-2; p  0.05).
n
nffect of rhNAP-2 on adhesion molecules and chemo-
ines in endothelial cells. As shown in Figures 5A and
B, rhNAP-2 significantly increased the protein levels of
-selectin and VCAM-1 in HUVECs. Concomitantly,
AP-2 strongly induced the release of MCP-1 and IL-8 in
hese cells (Figs. 5C and 5D). Neutralizing antibodies
gainst CXCR1 and CXCR2 attenuated the NAP-2-
ee plasma of unstimulated (Unstim) and SFLLRN-stimulated (100 M)
) (black bars), 12 patients with stable AP (striped bars), and 10 healthy
opolysaccharide (LPS) (10 ng/ml) and phytohemagglutinin (PHA) (final
culturing for 20 h in 12 patients with unstable AP (black bars), 12 patients
a are mean  SEM. *p  0.05 and **p  0.01 versus unstimulated cells;
by Scheffe’s post hoc test for statistical significance was used for statistical
igure 3. Photomicrographs showing staining and localization of
eutrophil-activating peptide-2, CXCR1, and CXCR2 in plaque sections
f left carotid artery. Plaque sections stained with omission of the primary
ntibody as control demonstrated no immunostaining of any of the cellular
lements (A). Fairly strong immunostaining of neutrophil-activating
eptide-2 (B), CXCR1 (C), and CXCR2 (D) was co-localized to areas
ith calprotecin-positive macrophages (E). No immunostaining was seen
n sections from non-atherosclerotic renal arteries when staining forlet-fr
is (AP
in lip
after
). Dat
lowedeutrophil-activating peptide-2, CXCR1, or CXCR2 (F). Original mag-
ification  400.
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NAP-2 in Coronary Artery Disease October 17, 2006:1591–9nduced increase in IL-8 levels by 41% and 43%, respec-
ively, indicating that this NAP-2-mediated effect involves
igation of both receptors (Fig. 5E). A similar pattern was
een for MCP-1 (data not shown). Recombinant NAP-2-
ctivated HUVECs showed a similar pattern of MCP-1
elease as was seen after rhIL-8 stimulation (data not
hown), suggesting that the inflammatory potential of
AP-2 may be comparable to that of IL-8.
latelet-derived NAP-2 promotes inflammation in endo-
helial cells. We next examined if platelet-derived NAP-2
ould mimic some of the inflammatory responses induced
y rhNAP-2. When HUVECs were incubated with platelet
xtracts, we found a marked up-regulation of IL-8 (Fig.
F). Whereas an unspecific antibody had only minor effect
n IL-8 expression, neutralizing antibody against NAP-2
ignificantly attenuated the effect of platelet extract on IL-8
evel, suggesting that it involves platelet-derived NAP-2
Fig. 5F). Similar pattern was seen for the platelet extract-
ediated effect on MCP-1 (data not shown).
ffects of aspirin and statins on NAP-2 levels. Finally,
e examined the effects of aspirin and statins on NAP-2.
igure 4. Photomicraphs showing staining and localization of neutrophil-
ctivating peptide-2, CXCR1, and CXCR2 in thrombus material removed
rom the site of plaque rupture in ST-segment elevation myocardial
nfarction patients undergoing percutaneous coronary intervention.
hrombus material stained with omission of the primary antibody as
ontrol demonstrated no immunostaining of any of the cellular elements
A). Fairly strong immunostaining of neutrophil-activating peptide-2 (B),
XCR1 (C), and CXCR2 (D) was seen in monocytes (arrows) and in
reas with platelets (*). (E) Demonstrates thrombus material with CD41-
ositive platelets, and (F) demonstrates calprotecin-positive monocytes.
riginal magnification  400.spirin (160 mg every day) significantly down-regulated tlasma levels of NAP-2 when given for 7 days in 11 healthy
ontrol subjects (Fig. 6A). In contrast, statins significantly
ncreased plasma levels of NAP-2 after 6 months of ther-
py in CAD patients receiving simvastatin (20 mg every
ay, n  21) or atorvastatin (80 mg every day, n 14) (11),
ith similar effect in both treatment groups (Fig. 6B). The
nhancing effect of statins on NAP-2 levels was seen also
n vitro with increasing effects of ortho-hydroxy atorvastatin
n gene expression of NAP-2 in PBMCs (Fig. 6C) and on
he release of NAP-2, but not the release of RANTES, in
FLLRN-stimulated (100 M) PRP from 5 healthy con-
rol subjects (Fig. 6D).
ISCUSSION
e report increased NAP-2 levels in angina patients with
articularly high levels in those with unstable disease,
ossibly reflecting enhanced release not only from platelets,
ut also from other cells involved in atherogenesis such as
onocytes/macrophages and vascular SMCs. The relation-
hip between raised NAP-2 levels and unstable disease was
urther supported by our immunohistochemical analyses
howing increased NAP-2 expression on platelets and
onocytes within thrombus material obtained at the site of
laque rupture in patients with STEMI undergoing PCI.
XCR1 and CXCR2 have previously been shown to play a
athogenic role in atherosclerotic disorders, mainly thought
o reflect their interaction with IL-8 (3,4). Our findings
uggest that also another ligand for these receptors (i.e.,
AP-2) could be involved in atherogenesis and plaque
estabilization. It may be argued that the high NAP-2 level
s a consequence rather than a cause of unstable angina.
owever, recent studies describe acute coronary syndromes
s a continuous process involving multiple ruptured athero-
clerotic plaques, not only in the culprit lesion (12). Hence,
lthough not the initial event, NAP-2-driven inflammation
ay contribute to the progression of patient instability
epresenting an amplification factor in this process.
Platelets have been regarded as the only cellular source of
AP-2, but also monocytes/macrophages have recently
een found to express NAP-2 (13). Herein, we extend these
ndings by showing that PBMCs, THP-1 macrophages,
nd vascular SMCs release NAP-2 upon various stimuli
uch as oxLDL, and the release of NAP-2 from PBMCs
as particularly enhanced in unstable angina patients. Al-
hough we cannot at present determine whether the elevated
AP-2 release reflects increased synthesis, enhanced gen-
ration of NAP-2 from its precursors, or both (14), our data
learly show the ability of other cells than platelets to
enerate NAP-2. Our findings of NAP-2 protein in mac-
ophages and SMCs within atherosclerotic carotid plaques
nd in monocytes of thrombus material obtained from the
ite of plaque rupture during MI further support that these
ells have the capacity to express NAP-2 and demonstrate
hat they do so in atherothrombosis.
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mportant steps in the recruitment and activation of leuko-
ytes into the atherosclerotic lesions (1). Herein, we show
hat NAP-2 is a potent inducer of E-selectin and VCAM-1
s well as the chemokines MCP-1 and IL-8 in endothelial
ells. This effect was induced not only by rhNAP-2, but also
y platelet-derived NAP-2. We found that monocytes from
nstable angina patients showed enhanced chemotactic
esponses to NAP-2, suggesting that the increased CXCR2
xpression in monocytes from these patients affects their
unctional responses. Our findings imply that the raised
igure 5. The effects of different concentrations of recombinant human
dhesion molecule (VCAM)-1 (B), monocyte chemoattractant protein (MC
fter culturing for 5 (A and B) and 24 h (C and D). (E) Shows the effec
n the rhNAP-2-induced (250 ng/ml) release of IL-8 in human umbilical
ffect was seen when a control antibody of the same isotype and concentrati
gainst NAP-2 and a control antibody of the same isotype and concentratio
elease in human umbilical vein endothelial cell supernatants after culturin
nd **p  0.001 versus unstimulated (Unstim) cells; #p  0.05 versus cells s
ank test (simple comparisonwise p values) was used for statistical comparAP-2 levels in unstable angina could contribute to en- aanced vascular inflammation within the atherosclerotic and
nstable lesion.
Experimental as well as some clinical data indicate that
tatins may confer cardiovascular benefits beyond their
ipid-lowering activity. These pleiotropic effects of statins
unction, in part, by attenuating inflammatory responses
11). However, our findings suggest that these medications
lso may exert inflammatory properties as also has been
eported by others (15). Thus, both aggressive and conven-
ional statin treatment significantly enhanced plasma levels
f NAP-2 in CAD patients after 6 months of therapy. Such
ophil-activating peptide (rhNAP)-2 on E-selectin (A), vascular cellular
(C), and interleukin (IL)-8 (D) in human umbilical vein endothelial cells
eutralizing antibodies against CXCR1 and CXCR2 (p  0.06) receptors
ndothelial cells supernatants after culturing for 24 h. No down-regulatory
s added (data not shown). (F) Shows the ability of a neutralizing antibody
1), to attenuate the effect of the platelet extract-mediated increase of IL-8
5 h. Data are mean values  SEM of 6 separate experiments. *p  0.05
ated with rhNAP-2 (E) or platelet extract (PE) (F). The Wilcoxon signed
OD  optical density.neutr
P)-1
t of n
vein e
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n (IgG
g for
timulNAP-2-enhancing potential was also supported by our in
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NAP-2 in Coronary Artery Disease October 17, 2006:1591–9itro experiments showing that ortho-hydroxy atorvastatin
nduced NAP-2 gene expression in PBMCs and NAP-2
elease in SFLLRN-activated platelets. The lack of effect on
he release of RANTES, another chemokine that is released
rom alpha-granules, suggests that statins may increase
AP-2 release from platelets by enhancing the conversion
rom its precursors or by attenuating NAP-2 degradation.
lthough we clearly do not argue against a beneficial role
or statins in CAD, these results suggest that other medi-
ations with another anti-inflammatory profile should be
nvestigated in these patients. Forthcoming studies should
lso examine if this NAP-2-enhancing effect is restricted to
ipophilic statins.
The present study has some limitations. Relatively few
atients were examined, and the patients groups were to a
ertain extent heterogeneous, for example with regard to the
se of platelet inhibitors. However, despite the use of more
ggressive platelet inhibition in the unstable angina patients,
hey still had markedly raised NAP-2 levels compared with
oth healthy control subjects and stable angina patients sug-
esting that our data represent an underestimation rather than
n overestimation of the “real” NAP-2 levels in these patients.
Our findings suggest that NAP-2 has the potential to
igure 6. (A) Shows the effect of aspirin (160 mg every day for 7 days) on
ubjects. Baseline level is set to 100% for each individual. (B) Shows plasm
f therapy with simvastatin (20 mg every day, n  21) or atorvastatin (80
ooled data from both treatment groups (means  SEM). (C) Shows the
AP-2 in peripheral blood mononuclear cells from 5 healthy control sub
mol/l) on SFLLRN-stimulated (100 mol/l) release of NAP-2 in platele
nd **p  0.01 versus unstimulated; #p  0.05 versus SFLLRN-stimulated
sed for statistical comparisons.nduce an inflammatory response within the atheroscleroticlaque. By its ability to promote leukocyte and endothelial
ell activation within the vessel wall, such a NAP-2-driven
nflammation could ultimately lead to plaque rupture and
cute coronary syndromes. Such a pathogenic NAP-2 loop,
nvolving interactions between platelets, leukocytes, and
ndothelial cells, could represent a potential target for
herapy in CAD.
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